Immunofoco Already Has a Phase 3 CAR-T. Now It’s Making Them Inside the Patient.
Immunofoco presented preclinical data for IMV102, an in vivo BCMA CAR-T built on its iMAGIC lentiviral platform.
Category Emerging Modalities
EpiBiologics Is Taking Extracellular Protein Degradation Into The Clinic
EpiBiologics dosed the first patient with EPI-326, a bispecific antibody degrader hitting wild-type and mutant EGFR.
Lilly Bought a Dual-Payload ADC Before It Hit the Clinic. Here’s Why.
Eli Lilly acquires CrossBridge Bio and its dual-payload ADC platform before any clinical data.
An Auger-Emitting Radioconjugate for Triple-Negative Breast Cancer
Cellectar Biosciences enrolls first patient in Phase 1b of CLR 125, an iodine-125 Auger emitter targeting refractory TNBC.
Deck Bio’s T Cell Engagers Target Multiple Intracellular Targets. That’s a Big Deal.
Deck Bio launches a multi-target pMHC T cell engager platform that hits multiple intracellular cancer antigens with a single binder.
“Cue” The Music. $7.5M for Picking the Right Molecule.
Cue Biopharma earns a $7.5M preclinical milestone from Boehringer Ingelheim for its CUE-501 autoimmune program.
An Oral Pill for Glioblastoma. From Oslo.
Hemispherian doses first patients in a Phase 1/2a trial of GLIX1, a first-in-class oral TET2 activator for glioblastoma.
One Patient. One B Cell. A Whole New Playbook.
Immusoft presents the world's first engineered B cell therapy patient data at an FDA workshop.
Edit the RNA. Keep the DNA. Fix the Disease.
AIRNA doses first patient in Phase 1 of AIR-001, an RNA-editing therapy for alpha-1 antitrypsin deficiency.
ADCs Hit a Wall. This Company Brought a Different Weapon.
ABION shows preclinical data at AACR 2026 where its IFN-β antibody fusion ABN202 outperformed TROP2 ADCs in resistant tumors.